Explore the latest in lung cancer, including advances in understanding epidemiology, risk factors, treatment biomarkers, and management.
This systematic review and meta-analysis examines US lung cancer screening adherence rates, patient characteristics associated with adherence, and diagnostic testing rates after screening.
This randomized phase 2 clinical trial assesses the efficacy and safety of plinabulin compared with pegfilgrastim for the prevention of chemotherapy-induced neutropenia following docetaxel chemotherapy in adult patients with non–small lung cancer.
This cross-sectional study examines whether Medicaid expansion is associated with improved mortality among patients with breast, colorectal, and lung cancer.
This cross-sectional study assesses the participation and detection rates of a lung cancer screening program in China and the factors associated with participation and detection among individuals at high risk for lung cancer.
This prospective observational study assesses changes in treatment plans for patients with lung cancer and qualifies the types of changes observed as a direct result of the coronavirus disease 2019 pandemic.
This cohort study uses data from the National Cancer Database to assess the association between adjuvant chemotherapy and survival in patients with node-negative early-stage non–small cell lung cancer (NSCLC) with vs without high-risk pathologic features.
This Viewpoint suggests a new dosage for pembrolizumab treatment that could decrease patients’ exposure risk to COVID-19.
This cohort study examines tumor mutational burden in patients with uncommon cancers not receiving immunotherapy as a biomarker associated with overall survival.
This multicenter cohort study characterizes the spectrum of multisystem immune-related adverse events, their association with survival, and risk factors for development, in patients with non–small cell lung cancer treated with immune checkpoint inhibitors.
This cohort study explores whether clinician specialty and patient familiarity with the attending clinician are associated with rates of low-dose computerized tomographic lung cancer screening after shared decision-making visits.
This systematic review and network meta-analysis clarifies which first-line treatment is associated with the best tumor response among patients with extensive-stage small cell lung cancer (SCLC).
This clinical trial assesses the clinical use of site-specific treatment, including molecularly targeted therapy based on next-generation sequencing results, for Japanese patients with cancer of unknown primary site.
This phase 1 trial assesses the safety, antitumor activity, and pharmacokinetics of toripalimab in patients with advanced non–small cell lung cancer (NSCLC) and evaluates the utility of JS311, a novel programmed death cell ligand 1 immunohistochemistry assay.
A 69-year-old man with a smoking history and complaints of back pain and cough for 2 weeks was found to have a right upper lobe lung mass with multiple lymphadenopathies. What is your diagnosis?
This nonrandomized clinical trial examines the inclusion of National Comprehensive Cancer Network (NCCN) guidelines in a tool used by patients with non–small cell lung cancer to facilitate decision-making.
This diagnostic study uses data from participants in the National Lung Screening Trial to assess the performance of a deep learning–based nodule detection algorithm for the detection of lung cancer on chest radiographs.
This cohort study evaluates whether the programmed death ligand 1 (PD-L1) gene copy number gains, comprising amplification and polysomy, in pretreatment specimens are associated with response to nivolumab monotherapy in patients with non–small cell lung cancer (NSCLC).
This systematic review and meta-analysis examines models using 6-month progression-free survival or objective response rate to estimate overall survival at 12 months in immune checkpoint inhibitor (ICI) randomized clinical trials.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: